[54]. In a phase I trial of 72 healthy volunteers, up to 48.6 mg of plecanatide was safe and 215 well-tolerated [55] . Currently, plecanatide is in phase III clinical trials for CIC and IBS-C 216 [56] . 217 218 Given their safety in human trials, these compounds could be used as oral-219 chemopreventive agents for CRC. In principle, exogenous GUCY2C ligand administration 220 would reconstitute the tumor-suppressing GUCY2C signaling axis, preventing colorectal 221 tumorigenesis. A phase I trial is underway to identify oral linaclotide dosing regimens that 222 stimulate GUCY2C in the rectum. Study participants receive a single oral dose of linaclotide 223 daily for 7 days, and then are assessed for increases in cGMP levels in rectal biopsy, as well 224 as safety and tolerability (Linaclotide Acetate in Preventing Colorectal Cancer in Healthy 225
Volunteers, clinicaltrials.gov NCT01950403). 226 227
GUCY2C-Targeted Immunotherapies for Metastatic Colorectal Cancer 228
While prevention of CRC remains the clinical ideal, therapeutic strategies for advanced 229 disease are also needed. A growing body of literature endorses immunotherapy for cancer 230 treatment. The immune system has a remarkable ability to suppress neoplastic 231 proliferation, as demonstrated by heightened cancer risk in immunocompromised patients 232 [57, 58] . In part, this risk reflects diminished immune control of oncogenic viruses (e.g. 233 human herpes virus 8 and Kaposi sarcoma, hepatitis B and C viruses and liver cancer, or 234 Epstein-Barr virus and Hodgkin's lymphoma) [58] ; however, these patients also are 235 predisposed to cancers without known infectious etiologies (e.g. melanoma, thyroid, and 236 colorectal cancers) [58] . Instead, these are thought to arise from poor immune surveillance 237 against cancer cells in tumors and the circulation. For example, the presence of 238 lymphocytes in CRC tumors is associated with delayed metastasis and prolonged survival 239 [59] . Tumor cells have a propensity to bypass or overcome these natural defense 240 mechanisms, creating an unmet need for therapies that improve the immune response to 241 cancer antigens (e.g. vaccines, adoptive T cell therapy) or target cancer cells directly (e.g. 242 immunotoxins) [60, 61] . 243 244 9 Effective CRC immunotherapies require antigenic targets that maximize immunogenicity 245 and minimize autoimmunity. The most explored target, the glycoprotein carcinoembryonic 246 antigen (CEA), is upregulated in CRC, but also appears in organs outside the GI tract, 247 leading to potential autoimmunity and immunological tolerance [62, 63] . In contrast, 248 GUCY2C has unique anatomic and biological characteristics that appear to circumvent 249 these issues. GUCY2C is expressed by intestinal mucosa from the small bowel to the rectum, 250
and is overexpressed in primary and metastatic colorectal neoplasms [30, 31, 32] . Further, 251 expression is largely restricted to the luminal aspect of the GI mucosa, and its extracellular 252 domain is antigenically distinct from other members of the guanylate cyclase family found 253 in other tissues [64, 65, 66] . Importantly, GUCY2C resides in an immune privileged 254 compartment, with minimal exposure to the systemic immune response [64, 65, 66] . 255
Limited cross-talk between systemic and mucosal immune elements protects normal 256 mucosa expressing GUCY2C from autoimmune toxicity, while also limiting systemic 257 tolerance to the antigen [64, 65, 66] . These advantages have led to the exploration of 258 several GUCY2C-targeted immunotherapeutic strategies (Figure 1) . 259 260
1 Vaccines 261
Similar to the yearly-recommended flu vaccine, cancer vaccines stimulate the immune 262 system to destroy cancer cells by targeting tumor-specific antigens, while also generating 263 long-lasting immunity [60] . Viral vector vaccines, engineered to contain the genes for 264 cancer antigens, enhance antitumor immunity by stimulating the expansion of adaptive 265 immune system elements, namely Type 1 CD4 + T-helper cells, cytotoxic CD8 + T cells and 266
antibodies [61] . This paradigm forms the basis for a GUCY2C-targeted vaccine, designed to 267 elicit immune responses to metastatic CRC. 268
269
The first GUCY2C-specific vaccine incorporated replication-deficient type 5 recombinant 270 adenovirus (Ad5) encoding the extracellular domain of GUCY2C (Ad5-GUCY2C) [64, 65, 66] . 271
In a murine pre-clinical proof-of-concept study, the vaccine stimulated a GUCY2C-specific 272 CD8 + cytotoxic T-cell response, which killed GUCY2C-expressing colon cancer cells. 273
Remarkably, survival in mice with lung and liver metastases improved, without signs of 274 inflammatory bowel disease, organ or metabolic dysfunction, or autoimmune tissue 275 damage [64] . Interestingly, the vaccine produced strong CD4 + T-cell, CD8 + T-cell, and B-cell 276 responses in Gucy2c -/-mice, but produced only a modest CD8 + T-cell response in Gucy2c +/+ 277 mice, which was attributed to GUCY2C-specific CD4 + T-cell tolerance [66] . To overcome 278 this, the vaccine was modified to include an immunogenic T-helper epitope from foreign 279 protein [66, 67] . This new vector reconstituted CD4 + T-cell, CD8 + T-cell, and memory 280 responses [66] . This was the first demonstration that selective CD4 + T-cell tolerance blocks 281 GUCY2C-specific immunity and memory responses. Importantly, this paradigm may extend 282 to other antigens, including those in melanoma and breast cancer, suggesting that 283 overcoming CD4 + T-cell tolerance may be a requirement in many cancer vaccine 284 approaches [66, 68, 69] . Epitope (Ad5-GUCY2C-PADRE). Preliminary findings are consistent with the pre-clinical 291 studies, with patients responding to the vaccine by producing GUCY2C-specific CD8 + T-cell 292 and B-cell responses, but not a CD4 + T-cell response, suggesting that selective CD4 + T-cell 293 tolerance governs GUCY2C-specific immune responses in humans, as well as mice [70] . 294
Moreover, like preclinical studies, the vaccine did not induce GUCY2C-targeted toxicity in 295 any GUCY2C-expressing tissue. Importantly, these first findings in humans support Ad5-296 GUCY2C-PADRE as a promising therapeutic approach for patients with GUCY2C-expressing 297 malignancies. 298 The next generation of antibody therapies, antibody-drug conjugates (ADCs) enable 344 targeted delivery of cytotoxic agents to specific tissues [89, 90] 
Conclusion 417
Despite improvements in CRC screening, incidence and mortality are among the highest of 418 all cancers, and while the genetic basis has been well described, therapeutic targets remain 419 elusive. The intestinal receptor GUCY2C has emerged as a target uniquely suited for 420 prevention, therapy, and diagnostics. Its role as a tumor suppressor, inactivated by ligand 421 loss early in tumorigenesis, suggests a novel disease prevention paradigm focused on 422
GUCY2C ligand replacement. A clinical program is underway ultimately to test this strategy 423
with the FDA-approved agent, linaclotide, and other promising agents are emerging. potentially targeting a universal CRC marker like GUCY2C as well as a marker of the stem 476 cell subpopulation may be a new translational avenue. As we better-characterize these 477 neoplastic markers, therapeutic strategies will continue to evolve. 478 479
Five Year View 480
A large body of work across multiple laboratories supports the hypothesis that GUCY2C 481 ligand loss is a necessary step in tumorigenesis. In the next five years, the molecular steps 482 in this process likely will be defined, potentially leading to new clinical targets. 483
Furthermore, results of the first trials translating GUCY2C-targeting schemes to the clinic 484 will become available, including the effectiveness of GUCY2C ligand supplementation with 485 linaclotide, a GUCY2C-targeted vaccine, a GUCY2C-targeted antibody-drug conjugate, and 486
GUCY2C-targeted CAR-T cells. Additional GUCY2C ligands (dolcanatide and plecanatide) 487
entering the pipeline will likely be explored for similar use as chemoprevention agents. 488
Ultimately, the next five years should provide the first insights into the potential for 489 GUCY2C-targeting to influence human colorectal cancer outcomes. 490 17 491
Key Issues 492
• The gastrointestinal epithelial receptor, guanylate cyclase C (GUCY2C) has been 493 described as a novel tumor suppressor and reliable biomarker of colorectal cancer. 494
• Endogenous GUCY2C ligand loss has been widely-described as an early step in 495 colorectal tumorigenesis, suggesting a therapeutic strategy of ligand replacement 496 for chemoprevention. The GUCY2C agonist linaclotide is FDA approved for other 497 indications and a phase I clinical trial examining its use for colorectal cancer 498 prevention is underway. 499
• GUCY2C is overexpressed in colorectal cancer metastases and several 500 immunotherapies targeting GUCY2C are being explored, including adoptive T-cell 501 therapy with GUCY2C-targeted CAR-T cells, a viral vector vaccine, and a GUCY2C-502 targeted antibody-drug conjugate. The latter two are currently in early human trials. 503
• Cancer staging and imaging strategies targeting GUCY2C also are being explored. 504 GUCY2C mRNA is a sensitive biomarker of occult lymph node metastases, improving 505 cancer detection and staging. 506 
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